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Abstract
Different glycoforms of some proteins have been identified as differential spots for certain diseases in 2-DE, indicating
disease-related glycosylation changes. It is routine to determine the site-specific glycosylation of nonsialylated N-
glycoproteins from a single gel spot, but some obstacles still exist in analyzing sialylated glycoproteins due to the lability
and higher detection limit of acid glycans in MALDI-TOF/TOF analysis. Thus, we present an improved protocol here. Tryptic
glycopeptides were separated and subjected to MALDI-TOF/TOF analysis, resulting in the identification of site-specific
glycosylation of high-intensity glycopeptides. Sequential deglycosylation and desialylation were used to improve the
identification of glycosylation sites and desialylated glycans. The site-specific glycosylation of large glycopeptides and low-
intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated
glycans. By applying it to 2-DE separated human serum, the difference of N-glycosylation was successfully determined for
a1-antitrypsin between different gel spots.
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Introduction
Of all known protein post-translational modifications (PTM),
glycosylation is indeed the most common and complex one, which
is predicted to occur on over 50% of all proteins and shows a great
of diversities[1]. The glycans of glycoproteins are very important
in many biological processes, such as embryonic development, cell
division processes and protein regulations and interactions [2,3].
The glycosylation status is crucial for protein functions, and it
changes significantly during inflammation, sepsis and cancers [4–
7]. It is important to monitor these changes and to find out how
they happen. Glycoproteins must be separated from complex
samples for detailed analysis. Despite that many technologies have
been developed recently, two-dimensional electrophoresis (2-DE)
remains one of the most efficient ways to conduct parallel
comparison and separate complex samples [8,9]. Thus, the
development of glycosylation analysis method for gel-separated
glycoproteins is imperative.
Presently, there are four types of known glycosylation, in which
N-glycosylation and O-glycosylation are the most common ones.
N-glycosylation occurs on asparagine residues in the consensus
sequence Asn-Xxx-Ser/Thr (sometimes also Cys) via an N-
acetylglucosamine residue, and Xxx can be any amino acid
except proline. After digestion with PNGase F, the NH2 group in
asparagine changes into OH group at the glycosylation site, and
the mass of deglycosylated peptides increases 0.984 Dalton, which
can be detected unambiguously with MALDI-TOF. In mammals,
sialic acids are added by the capping reaction, and they are very
important in cell-cell interactions. It is reported that the number of
sialic acid moieties changes significantly during acute and chronic
diseases, indicating that sialylated glycoproteins may be biomarker
candidates [10,11]. One sialylated glycoprotein is often separated
into a string of spots with different pI values in 2-DE due to the
different number of terminal sialic acids [12–14], and some of its
glycoforms are identified as differential spots for certain diseases
[4,15–17]. Thus, it is important to elucidate the glycosylation
information of the differential spots, which may be crucial in
understanding the mechanism of related diseases and be identified
as biomarkers.
Generally, glycoprotein characterization includes several steps, i.e.
protein identification, determination of glycosylation sites and
evaluation of site-specific microheterogeneities. Larsen et al. intro-
duced a fast and sensitive method to characterize gel-separated
nonsialylated N-glycoproteins [18]. However, it cannot be applied
directly to sialylated glycoproteins because sialylated structures can
lose a significant amount of sialic acids easily in the ion source or after
the ion extraction from the ion source [2]. In recent years, many
efforts have been made to analyze gel-separated sialylated glycopro-
teins. For example, von Witzendorff et al. identified the N-linked
glycans of porcine zona pellucida glycoprotein ZPA with MALDI-
TOF by desialylating them firstly, but it was impossible to determine
the number of terminal sialic acids [19]. Permethylation or
esterification of sialylated glycans could stabilize them and improve
their detection with MALDI-TOF, but generally the amount of 2-DE
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usingHILIC to extract glycopeptides was successfully employed in the
analysis of gel-separated sialylated glycoproteins [20], but it failed to
analyze large glycopeptides over 4000 Dalton and low-abundance
glycopeptides.
Here we introduced an improved protocol to enhance the
analysis of large glycopeptides over 4000 Dalton and low-
abundance glycopeptides of which the site-specific glycosylation
could not be determined with MS/MS. In this study, the
composition of these glycopeptides was deduced based on the
masses of glycopeptides, deglycosylated peptides and desialylated
glycans. The sequential deglycosylation and desialylation greatly
improve the detection of deglycosylated peptides and desialylated
glycans. In addition, improved peptide desalting and neutral
glycan identification methods were utilized in the protocol, which
further enhanced its overall sensitivity. It was verified with 10 pmol
gel-separated human transferrin and a1-antitrypsin spots from 2-
DE separated human serum proteins.
Materials and Methods
Ethics Statement
The use of human sera for proteomics research was approved
by the Institutional Review Board (IRB) of Beijing Institute of
Genomics and informed consent was given by the participant in
written.
Materials
Human transferrin, a-cyano-4-hydroxycinnamic acid (CHCA),
2,5-dihydroxybenzoic acid (DHB), 2,4,6-trihydroxyacetophenone
Monohydrate (THAP), diammonium citrate (DAC) and PNGase F
were purchased from Sigma. Sialidase was purchased from
Calbiochem. To pack microcolumns, HILIC material (ZIC
TM-
HILIC, 200 A ˚,1 0mm, SeQuant AB, Sweden), Poros R2 material
(20 mm, Applied Biosystems, USA) and graphitized carbon
(obtained from dismantled Carbograph (Alltech, USA)) were
packed in constricted GELoader tips (Eppendorf, Hamburg,
Germany) as described [21]. CostarH Microcentrifuge tubes were
purchased from Corning Incorporated. All other materials were
purchased from Sigma unless otherwise described. The water was
from a Milli-Q system (Millipore, USA). Human serum was taken
from a healthy human.
Gel Electrophoresis and In-gel Tryptic Digestion
Forone-dimensionalelectrophoresis, 5 pmoland10pmol human
transferrin was loaded, respectively. For 2-DE, 10 mL untreated
human serum was loaded to each strip (7 cm, pH 4.7–5.9) for
analyzing human a1-antitrypsin. The isoelectric focusing and 2-DE
PAGEwereconducted as described [4]. Proteins werefixed, stained
and destained according to the cautions described by Kuster et al,
and all the solutions should not contain over 7.5% acetic acid in
order to preserve sialic acid-containing glycans [22]. Protein spots
were then cut separately, and in-gel tryptic digestion was conducted
as described except that trypsin was added at the ratio of 1:30 [4].
Enrichment of glycopeptides
Peptides and glycopeptides were extracted from gel particles
under sonication for 20 minutes with 50% ACN containing 0.1%
TFA twice [19]. The combined extracts were dried down in vacuo
and redissolved in 80% ACN, 2% formic acid (FA). A 1-mL
disposable syringe was used to force the liquid through self-packed
microcolumns. After HILIC microcolumns were equilibrated by
80% ACN, 2% FA, the redissolved samples were loaded onto
HILIC microcolumns slowly, washed with 40 mL equilibration
buffer, and eluted with 2.5 mL 2% FA. About 0.6 mL glycopeptides
were mixed with 0.6 mL DHB matrix on Bruker #25184 MALDI
target and dried in air.
Deglycosylation of glycopeptides
The rest of the HILIC enriched glycopeptides from the above
step were dried in vacuo and redissolved in 20 mL2 0 m M
NH4HCO3, pH 8.0. To the solution, 1 mL PNGase F (5 U/
100 mL) was added and incubated at 37uC overnight. One
microliter of the digested samples was used to identify deglyco-
sylated peptides on Bruker Anchorchip
TM target.
Desialylation of sialylated glycans
After the above-mentioned PNGase F digested samples passed
through a Poros R2 microcolumn, the flow-through was treated
with 0.05N HCl at 70uC for one hour to remove sialic acids [23].
Alternatively, sialidase could also be used to remove sialic acids.
After the flow-through of Poros R2 microcolumn was dried and
redissolved in 50 mM sodium acetate containing 1 mM CaCl2,
pH 5.5, 5 mL sialidase (1 U/mL) was added. It was then incubated
at 37uC overnight for complete removal of sialic acids.
Purification of desialylated glycans
The glycan purification procedure followed previously de-
scribed method [24]. After graphitized carbon microcolumns were
equilibrated with water, the HCl treated or sialidase digested
glycans were loaded into it slowly, washed with water, and eluted
with 30% ACN, 0.1% TFA. The eluate was then dried in vacuo
and redissoved in water.
Matrix Preparation
The CHCA matrix was prepared by dissolving 4 mg of CHCA
in 1 mL of 70% ACN/0.1% TFA. The DHB matrix was prepared
by dissolving 10 mg of DHB in 1 mL of 50% ACN/0.1% TFA.
The THAP matrix was prepared by dissolving 7.5 mg of THAP in
1 mL of ACN/20 mM ammonium citrate (1:1 v/v).
Sample preparation
For peptides, 0.5 mL samples were applied on AnchorChip
TM
target (Bruker Daltonics, Germany). After they were dried, about
0.1 mL CHCA matrix was added. The dried target was desalted by
washing with 0.1% TFA twice and subjected to MS analysis.
Glycopeptide samples were prepared as above mentioned. For
glycans, 0.5 mL samples were applied to Bruker #25184 MALDI
target, and then 0.5 mL of THAP was added. They were dried
under vacuum (50610
23 Torr) after mixed adequately with
pipette tips. After vacuum drying, the sample appeared translu-
cent. Upon absorption of moisture, the sample formed small
crystals [25].
MALDI-MS
MALDI-MS (/MS) data were obtained by an Ultraflex mass
spectrometer (Bruker Daltonics, Germany). For peptide mass
fingerprint (PMF) identification, the mass spectrometer was
externally calibrated in order to reach the mass accuracy of
100 ppm. The database searches were performed against NCBInr
database using Mascot software with fixed modification as
carbamidomethyl (C) and variable modifications as oxidation
(M). Desialylated glycans were analyzed in the same way with
peptides. Glycopeptides were analyzed in the m/z range of 2000–
7000 in the linear positive-ion mode. External calibration was
performed using the average values of 5 tryptic peptides or
glycopeptides of horseradish peroxidase, and the mass accuracy of
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were added to obtain the final specta. The mass signals were
manually annotated. MS/MS analysis in the TOF/TOF mode
was conducted as described [4].
Estimation of glycan composition and determination of
glycopeptides
Estimation of N-linked glycan composition was accomplished by
input of the peak masses into the GlycoMod Tool (http://www.
expasy.org/tools/glycomod/). The masses of peptides and desia-
lylated glycans were obtained in monoisotopic value in the
reflectron mode of MALDI-TOF. However, because the masses of
glycopeptides were obtained in average value in the linear mode of
MALDI-TOF, the monoisotopic value of peptides and desialylated
glycans must be turned into average values before calculation.
Thus, we annotated their spectra manually with specific
annotation method in order to get that average values. Finally, if
the measured mass of a glycopeptide was equal to or 291*X
(X=1, 2, 3…) more than the predicted mass of a potential
glycopeptide, i.e. different combinations of deglycosylated peptides
and desialylated glycans, the potential glycopeptide should really
exist, and the number of terminal sialic acids was X. The
calculation is based on the fact that a glycopeptide is actually
composed of three parts, i.e. the peptide part, the glycan part with
sialic acids removed and the released sialic acids. The acceptable
error was 500 ppm in the calculation.
Results
Principles of the Method
The strategy for analysis of gel-separated sialylated glycopro-
teins was illustrated in Figure 1. Briefly, after protein spots were
digested by trypsin, some samples were used for PMF identifica-
tion on Bruker Anchorchip
TM target, which was proved to be
efficient in peptide concentration [26]. We then predicted both
potential N-glycosylation sites and the masses of potential
deglycosylated peptides based on protein sequence. The MS
signals of unmodified peptides tended to suppress that of
glycopeptides, especially when glycopeptides contained sialylated
glycans [27]. Thus, it was necessary to separate glycopeptides from
other peptides by using HILIC materials, which was proved to be
effective in glycopeptide enrichment [28]. Sialylated glycopeptides
were generally analyzed in the linear mode of MALDI-TOF
because of its easy loss of sialic acids in the reflectron mode[2].
However, as shown in Figure 2C and 2D, we found a new way to
conduct MS/MS analysis on sialylated glycopeptides in the
reflectron mode so that the number of terminal sialic acids,
glycosylation sites and the linked glycans were obtained for high-
intensity glycopeptides. The remaining glycopeptides were then
deglycosylated with PNGase F. Some of the samples were used for
MS and MS/MS analysis of deglycosylated peptides to confirm
the glycosylation sites. After the remaining PNGase F digested
samples passed through a Poros R2 microcolumn, we got the
solution of sialylated glycans. Although Papac et al. reported that
THAP was the best matrix in the analysis of sialylated glycans with
MALDI-TOF [25], it was still impossible to identify sialylated
glycans unambiguously from gel-separated proteomic level
glycoproteins. Consequently, sialic acids were removed with HCl
or sialidase digestion for enhancing the mass signals. Finally,
desialylated glycans were purified with graphitized carbon
microcolumns and analyzed with MALDI-TOF in the reflectron
mode. After input of their masses into GlycoMod, we got their
corresponding compositions. Because MS/MS analysis could not
be effectively conducted on large glycopeptides or low-intensity
glycopeptides, we had to predict their composition based on the
masses of glycopeptides, deglycosylated peptides and desialylated
glycans or deduce their composition based on their mass difference
with the identified high-intensity glycopeptides. However, as
shown in Figure 2C, we could also confirm the number of
terminal sialic acids by collecting their parent ions in TOF/TOF
mode. N-glycosylation analysis of gel-separated sialylated glyco-
proteins would be successfully accomplished with the protocol.
To demonstrate the efficiency of the strategy, human transferrin
was chosen as the model protein because its glycosylation status
has been analyzed in details in a multi-institutional study [29].
Compared to about 100 pmol samples used for glycopeptide
characterization in that study, only 10 pmol samples were used in
our protocol, and most low-abundance glycans around 1 percent
as well as their glycosylation sites were successfully determined
[29], indicating a significant increase of the detection sensitivity.
PMF Identification
By conducting MS analysis on trypsin digested gel-separated
samples, we got their MS spectra. Human transferrin was
identified with the sequence coverage of 68%. Because N-
glycosylation occurs in the consensus sequence Asn–Xxx–Ser/
Thr (sometimes also Cys), we predicted potential glycosylation sites
and the theoretical mass of the corresponding deglycosylated
peptides from the sequence, i.e. 1477.744 (Asn-432), 3530.654
(Asn-432, with one missed cleavage), 700.328 (Asn-491) and
2516.117 (Asn-630). In the following, the prediction would be
confirmed by MS or MS/MS analysis on deglycosylated peptides.
MS and MS/MS analysis of glycopeptides
When glycopeptides enriched from gel-separated human
transferrin were analyzed with MALDI-TOF, the mass spectra
shown in Figure 2A–B were obtained. In a comparison to the
recent published data [29], nearly all the glycopeptides of human
transferrin were identified with much less samples except for the
glycopeptide of m/z 4340.3, which owned a very low percentage
Figure 1. The strategy for N-glycosylation analysis of gel-
separated sialylated glycoproteins.
doi:10.1371/journal.pone.0015096.g001
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were successfully identified with the improved protocol.
As shown in Figure 2C, when the precursor of m/z 3684.6 was
collected with the LIFT method of Bruker Ultraflex, three major
signals were obtained, i.e. m/z 3100.5, 3391.6 and 3682.3. The
difference between the adjacent signals was about 291. Because
sialic acids tended to lose when analyzed with MALDI-TOF in the
reflectron mode, it was deduced that the glycopeptide had two
terminal sialic acids. We then conducted MS/MS analysis on the
glycopeptide losing sialic acids, i.e. m/z 3100.5. Generally,
MALDI–TOF/TOF–MS of N-glycopeptides results in a set of
cleavages at or near the innermost N-acetylglucosamine residue,
with all the fragment ions retaining the peptide moiety so that four
characteristic signals were generated, i.e. [Mpep+H217]
+,
[Mpep+H]
+,[ M pep+H+83]
+ and [Mpep+H+203]
+ [23,30]. The
characteristic peak pattern of delta 17-83-120Da is unique in the
MS/MS spectrum of N-glycopeptides so that [Mpep+H]
+ can be
determined, which leads to the identification of glycosylation sites.
As shown in Figure 2D, because the deference between m/z
1459.6, 1476.7, 1559.7 and 1679.6 was about 17, 83 and 120
respectively, and m/z 1476.7 was equal to the predicted mass of
certain unglycosylated peptide, i.e. CGLVPVLAENYNK (Asn-
432), they were identified as the four characteristic signals in the
MS/MS of N-glycopeptides. Thus, the glycosylation site of the
glycopeptide was determined. The glycan structure of the
glycopeptide was deduced based on the difference between
adjacent mass signals in MS/MS spectrum and the biosynthesis
process of glycans. We also conducted MS/MS analysis on m/z
4724.0 (data not shown). As with previous studies, its glycan
composition could not be deduced from MS/MS because of
insufficient dissociation, but the glycosylation site and number of
terminal sialic acids were unambiguously identified. It is a
significant improvement compared with previous analysis meth-
ods. The glycan composition of the glycopeptide was then
determined based on its mass and that of deglycosylated peptides
and desialylated glycans obtained later.
Figure 2. MS and MS/MS spectra of glycopeptides from 10 pmol gel-separated human transferrin. (A) Mass spectrum of the
glycopeptides of human transferrin. (B) The enlarged view of Figure 2A, which shows low-abundance glycopeptides more clearly. (C) Mass spectrum
of the parent ion of m/z 3684.6 obtained in TOF/TOF mode. The difference between 3682.3, 3391.6 and 3100.5 is about 291. (D) MS/MS spectrum
from the precursor indicated by arrow in Figure 2C. The mass of [Mpep+H]
+ was 1476.7. Glycan structures were deduced based on the difference
between adjacent signals and its biosynthesis process.
doi:10.1371/journal.pone.0015096.g002
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By comparing the masses of deglycosylated peptides in
Figure 3A with their theoretical masses, m/z 1477.681,
2516.072 and 3530.644 were identified as deglycosylated peptides.
MS/MS analysis was conducted on m/z 2516.072 to further
confirm it, and the mass spectrum in Figure 3B was obtained.
After searching the masses against NCBInr database using Mascot
software, the peptide of QQQHLFGSDVTDCSGNFCLFR (Asn-
630) was identified with a score of 87, and individual ions scores
.34 indicate identity or extensive homology (p,0.05). These
results further confirmed our prediction about glycosylation sites.
MS analysis of desialylated glycans
We got the mass spectrum in Figure 3C while analyzing the
graphitized carbon purified desialylated glycans using THAP as
the matrix with MALDI-TOF in the reflectron mode. The
composition of desialylated glycans was predicted based on the
mass search in GlycoMod. For example, the composition of m/z
1664.500 was predicted to be (Hex)2 (HexNAc)2+ (Man)3(-
GlcNAc)2 with an error of 20.005 Da; that of m/z 1810.793 was
(Hex)2 (HexNAc)2 (Deoxyhexose)1+ (Man)3(GlcNAc)2 with an
error of 0.144 Da; that of m/z 2029.734 was (Hex)3 (HexNAc)3+
(Man)3(GlcNAc)2 with an error of 20.108 Da. The accuracy of
the prediction is assured due to the small deviation from
theoretical values. Their structures shown in Figure 3C were
predicted based on the biosynthesis process of N-glycans in
mammals and the comparison with known glycan structures.
Assignment of glycopeptides
The calculation method mentioned in ‘‘Materials and Meth-
ods’’ was used to analyze glycopeptides. Since the masses of
glycopeptides can only be obtained in average values in the linear
mode of MALDI-TOF/TOF, the monoisotopic values of
deglycosylated peptides obtained in the reflectron mode must be
turned into average values before the calculation. As shown in
Table 1, we firstly turned the monoisotopic value of deglycosylated
peptides into average value, and then calculated MPG (the masses
of potential glycopeptides), MPG+291, MPG+291*2 and
MPG+291*3 respectively. After comparing these values with the
measured masses of glycopeptides from human transferrin, most
glycopeptides were identified except for m/z 5234.1 and 5525.9.
Base on the difference between m/z 5234.1 and 5088.7 and that
between m/z 5234.1 and 5525.9, they were also identified (See
also Figure 2B). The number of terminal sialic acids was confirmed
by MS/MS analysis of low-intensity glycopeptides. Now, all the
glycopeptides were identified for gel-separated human transferrin.
N-glycosylation analysis of 2-DE gel-separated human
a1-antitrypsin
In order to prove that our protocol was also applicable to 2-DE
separated samples, we applied it to human a1-antitrypsin from
10 mL normal human serum separated by 2-DE (Figure 4A). The
two largest spots of a1-antitrypsin were chosen for analysis, and
they were named as A1PI-1 and A1PI-2 from low pI to high pI.N -
glycans on all three glycosylation sites of human a1-antitrypsin
were determined successfully for both spots using our improved
protocol. The mass spectra of the glycopeptides of A1PI-1 and
A1PI-2 were listed between 5500 and 7000 Dalton in Figure 4B
and 4C because they had differences only in the range. Compared
with A1PI-1, the relative abundance of diantennary N-glycans
indicated by arrows in A1PI-2 in figure 4C increased significantly,
while that of the triantennary N-glycans decreased significantly.
Figure 3. MS and MS/MS spectra of deglycosylated peptides and desialylated glycans of human transferrin. (A) Mass spectrum of
deglycosylated peptides of human transferrin, m/z 1477.681, 2516.072 and 3530.644 were identified as deglycosylated peptides. (B) MS/MS spectrum
of m/z 2516 indicated by arrow in Figure 3A. (C) Mass spectrum of desialylated glycans of human transferrin. The MS signals were [M+Na]
+ ions in
average values, and corresponding structures were also shown.
doi:10.1371/journal.pone.0015096.g003
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Table 2. The glycosylation analysis of 2-DE separated human a1-
antitrypsin indicated that there were more triantennary glycans
with two or three terminal sialic acids and less diantennary glycans
in 2-DE spots with lower pI for the same protein, which was
consistent with previous research work [31].
Table 1. The mass of potential glycopeptides of human transferrin calculated from that of deglycosylated peptides and
desialylated glycans.
[Mpep+H]
+
mono [Mpep+H]
+
avg [Mglycan+Na]
+
avg [MPG+H]
+
avg
[MPG+H]
+
avg
+291
[MPG+H]
+
avg
+291*2
[MPG+H]
+
avg
+291*3
1477.681
(Asn-432)
1478.700 1664.500
1810.793
2029.734
3101.200
3247.493
3466.434
3392.200
3538.493
3757.434
3683.200
3829.493
4048.434
3974.200
4120.493
4339.434
2516.072
(Asn-630)
2517.773 1664.500
1810.793
2029.734
4140.273
4286.566
4505.507
4431.273
4577.566
4796.507
4722.273
4868.566
5087.507
5013.273
5159.566
5378.507
3530.644
(Asn-432)
3532.958 1664.500
1810.793
2029.734
5155.458
5301.751
5520.692
5446.458
5592.751
5811.692
5737.458
5883.751
6102.692
6028.458
6174.751
6393.692
MPG: Mass of potential glycopeptides.
Note: The measured masses of the glycopeptides of human transferrin are 3393.0, 3684.6, 4049.4, 4142.9, 4432.1, 4576.6, 4724.0, 4871.2, 5088.7, 5234.1, 5381.8, 5525.9,
5738.8 and 5884.1. The values in bold are identified glycopeptides.
doi:10.1371/journal.pone.0015096.t001
Figure 4. 2-DE image of 10 mL human serum and mass spectra of glycopeptides of 2-DE separated a1-antitrypsin. (A) 2-DE image of
10 mL human serum. Two largest spots of a1-antitrypsin were chosen for glycosylation analysis and named as A1PI-1 and A1PI-2. (B)–(C): Mass spectra
of the glycopeptides of A1PI-1 and A1PI-2 in the mass range of 5500-7000 Dalton. Data were shown in average value. Compared with A1PI-1, the
relative abundance of diantennary N-glycans indicated by arrows in A1PI-2 increased significantly, while the triantennary N-glycans decreased
significantly.
doi:10.1371/journal.pone.0015096.g004
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Both N-glycosylation sites and site-specific microheterogeneities
were determined unambiguously from 10 pmol gel-separated
human transferrin band using the improved protocol. We also
tried 5 pmol samples as the lower limit. Although glycopeptides
could also be identified, it was insufficient for the subsequent
deglycosylation and desialylation. It was a little difficult to get 10
pmol samples from 2-DE gel spots, but sufficient samples could be
obtained for glycosylation analysis by applying different amount of
samples on gels for protein identification and glycosylation
analysis, respectively [32]. By applying the presented protocol to
human lactoferrin, a widely studied glycoprotein, 6 new low-
abundance glycans were discovered (unpublished data), which
validated the sensitivity of the protocol. The desialylation
treatment improves the detection of N-glycans greatly.
In the past, many researchers used to desalt peptides by Poros
R2 or graphite powder before MALDI-TOF analysis. It is a simple
and convenient method. However, in this study, Bruker
Anchorchip
TM target was utilized in desalting peptides because
its workflow was more simple and time-saving, which is consistent
with the great number of proteomic protein identification.
Furthermore, it is better in preserving small hydrophilic peptides
that are generally lost during the desalting with other methods.
Thus, higher protein sequence coverage was obtained in PMF
identification [26]. In the enrichment of glycopeptides, HILIC is
more efficient than the generally used agarose bound lectins in the
nano-scale analysis because of its smaller particle size (10 mmv s
200–300 mm), which is consistent with the extremely low amount
of samples from 2-DE spots. Moreover, HILIC enriches
glycopeptides because of their hydrophilic property but not
specific glycan structures. Thus, it is the material of choice for
overall glycopeptide enrichment [30]. Recently, magnetic beads
functionalized with di-boronic acid, ConA and WGA were
developed by Bruker Daltonics Inc., but they could not be used
in the nano-scale enrichment of glycopeptides [33].
Papac et al. reported that 50 fmol sialylated glycans were
detected with signal-to-noise ratio of better than 5:1 with MALDI-
TOF when THAP was used as the matrix[25], but it was still
impossible to identify sialylated glycans unambiguously from a
single gel-separated sialylated glycoprotein spot. The possible
explanation is that when the amount of proteins is in the low
picomole level, the loss of them is much more significant during
the preparation, such as attachment on GEloader tips and pipette
tips. Thus, we chose to desialylate acid glycans in order to improve
their detection. The desialyation with HCl was quick and efficient.
However, some contaminant signals less than 1500 Dalton
appeared occasionally. The possible reason is that the polypro-
pylene tubes may degrade at the high temperature of 70uC. Thus,
a glass bottle should be a better choice. Alternatively, if sialidase
was used for desialylation, the occurrence of contaminant signals
could be avoided, but the incubation period was much longer.
Generally, many researchers used DHB or Super-DHB as the
matrix in the analysis of neutral glycans [12,25,34]. However, based
on our results, THAP/DAC provides a better result in the MS
analysis of neutral glycans, which achieves better signal-to-noise
ratio and signal intensity with same amount of glycans. And it also
provides better shot-to-shot and sample-to-sample reproducibility.
However, it has not been widely employed yet because it is rather
difficult to get small crystals while using THAP as the matrix. The
mixture of glycans and THAP must be dried immediately in high
vaccum after mixed completely. Otherwise, large crystals will form,
and no mass signals of glycans can be obtained.
One disadvantage of our protocol is that it provides no direct
information about monosaccharide type and glycan linkage type.
Generally, it needs to conduct permethylation, NMR research or
sequential glycosidase digestion on glycans in order to get the
detailed information, but gel-separated samples are surely
insufficient for the treatments. In our protocol, glycan composition
was determined accurately. Considering the biosynthesis process
of glycans and known glycan structures in public databases, we
could also get their structures. The site-specific glycosylation of
large glycopeptides and low-abundance glycopeptides was mainly
deduced from MS data but not from MS/MS due to the limitation
of current mass spectrometers. In future, it is expected that MS/
MS can be successfully done on these glycopeptides with MALDI-
TOF/TOF with the quick development of mass spectrometers.
Our protocol has extended the previous protocol to the analysis
of large glycopeptides over 4000 Dalton and low-abundance
glycopeptides. The sequential deglycosylation and desialylation
improve the identification of glycosylation sites and glycans
greatly. It is sensitive enough to analyze gel-separated sialylated
glycoproteins, especially different glycoforms of the same glyco-
protein separated by 2-DE. It can also be used in the glycosylation
analysis of purified or recombinant glycoproteins due to its
excellent sensitivity. It is reported that many potential biomarkers
for cancers and inflammation are glycoproteins with different
glycosylation status [10,11,35]. The elucidation of glycosylation
status of glycoproteins will be helpful to understand the
mechanism of certain diseases and identify potential biomarkers.
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Table 2. Relative abundance (%) of the glycans identified at Asn107 of human a1-antitrypsin
a.
I II III IV V VI VII
Carbohydrate
Structure on Asn107
A1PI-1 7.4% 25.8% 4.8% 19.3% 4.8% 30.2% 7.8%
A1PI-2 14.9% 69.9% 7.2% 2.9% 1.3% 2.8% 1.1%
aApproximate abundance was estimated using MS signal intensities from a single analysis.
doi:10.1371/journal.pone.0015096.t002
Improved Analysis of Gel-Separated Glycoproteins
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e15096References
1. Apweiler R, Hermjakob H, Sharon N (1999) On the frequency of protein
glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim
Biophys Acta 1473: 4–8.
2. Morelle W, Canis K, Chirat F, Faid V, Michalski JC (2006) The use of mass
spectrometry for the proteomic analysis of glycosylation. Proteomics 6:
3993–4015.
3. Uematsu R, Furukawa J, Nakagawa H, Shinohara Y, Deguchi K, et al. (2005)
High throughput quantitative glycomics and glycoform-focused proteomics of
murine dermis and epidermis. Mol Cell Proteomics 4: 1977–1989.
4. Ren Y, Wang J, Xia J, Jiang C, Zhao K, et al. (2007) The alterations of mouse
plasma proteins during septic development. J Proteome Res 6: 2812–2821.
5. Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation–potential
for therapeutics and diagnostics. Nat Rev Drug Discov 4: 477–488.
6. Chen Y, Lim BK, Hashim OH (2009) Different altered stage correlative
expression of high abundance acute-phase proteins in sera of patients with
epithelial ovarian carcinoma. J Hematol Oncol 2: 37.
7. Lee CW, Lin MY, Lee WC, Chou MH, Hsieh CS, et al. (2007) Characterization
of plasma proteome in biliary atresia. Clin Chim Acta 375: 104–109.
8. Gorg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis
technology for proteomics. Proteomics 4: 3665–3685.
9. Graham DR, Mitsak MJ, Elliott ST, Chen D, Whelan SA, et al. (2008) Two-
dimensional gel-based approaches for the assessment of N-Linked and O-
GlcNAc glycosylation in human and simian immunodeficiency viruses.
Proteomics 8: 4919–4930.
10. Iijima S, Shiba K, Kimura M, Nagai K, Iwai T (2000) Changes of alpha1-acid
glycoprotein microheterogeneity in acute inflammation stages analyzed by
isoelectric focusing using serum obtained postoperatively. Electrophoresis 21:
753–759.
11. Herve F, Duche JC, Jaurand MC (1998) Changes in expression and
microheterogeneity of the genetic variants of human alpha1-acid glycoprotein
in malignant mesothelioma. J Chromatogr B Biomed Sci Appl 715: 111–123.
12. Sagi D, Kienz P, Denecke J, Marquardt T, Peter-Katalinic J (2005)
Glycoproteomics of N-glycosylation by in-gel deglycosylation and matrix-
assisted laser desorption/ionisation-time of flight mass spectrometry mapping:
application to congenital disorders of glycosylation. Proteomics 5: 2689–2701.
13. Vanderver A, Schiffmann R, Timmons M, Kellersberger KA, Fabris D, et al.
(2005) Decreased asialotransferrin in cerebrospinal fluid of patients with
childhood-onset ataxia and central nervous system hypomyelination/vanishing
white matter disease. Clin Chem 51: 2031–2042.
14. Ghafouri B, Irander K, Lindbom J, Tagesson C, Lindahl M (2006) Comparative
proteomics of nasal fluid in seasonal allergic rhinitis. J Proteome Res 5: 330–338.
15. Abdul-Rahman PS, Lim BK, Hashim OH (2007) Expression of high-abundance
proteins in sera of patients with endometrial and cervical cancers: analysis using
2-DE with silver staining and lectin detection methods. Electrophoresis 28:
1989–1996.
16. Chen Y, Lim BK, Peh SC, Abdul-Rahman PS, Hashim OH (2008) Profiling of
serum and tissue high abundance acute-phase proteins of patients with epithelial
and germ line ovarian carcinoma. Proteome Sci 6: 20.
17. Chen CB, Su YC, Huang TT, Ho HC, Chang YT, et al. (2008) Differentially
expressed serum haptoglobin alpha chain isoforms with potential application for
diagnosis of head and neck cancer. Clin Chim Acta 398: 48–52.
18. Larsen MR, Hojrup P, Roepstorff P (2005) Characterization of gel-separated
glycoproteins using two-step proteolytic digestion combined with sequential
microcolumns and mass spectrometry. Mol Cell Proteomics 4: 107–119.
19. von Witzendorff D, Ekhlasi-Hundrieser M, Dostalova Z, Resch M, Rath D,
et al. (2005) Analysis of N-linked glycans of porcine zona pellucida glycoprotein
ZPA by MALDI-TOF MS: a contribution to understanding zona pellucida
structure. Glycobiology 15: 475–488.
20. Morten TA, Hojrup P (2006) Enrichment and Characterization of Glycopep-
tides from Gel-Separated Glycoproteins. American Biotechnology Laboratory
24.
21. Gobom J, Nordhoff E, Mirgorodskaya E, Ekman R, Roepstorff P (1999) Sample
purification and preparation technique based on nano-scale reversed-phase
columns for the sensitive analysis of complex peptide mixtures by matrix-assisted
laser desorption/ionization mass spectrometry. J Mass Spectrom 34: 105–116.
22. Kuster B, Wheeler SF, Hunter AP, Dwek RA, Harvey DJ (1997) Sequencing of
N-linked oligosaccharides directly from protein gels: in-gel deglycosylation
followed by matrix-assisted laser desorption/ionization mass spectrometry and
normal-phase high-performance liquid chromatography. Anal Biochem 250:
82–101.
23. Rohrer JS, Thayer J, Weitzhandler M, Avdalovic N (1998) Analysis of the N-
acetylneuraminic acid and N-glycolylneuraminic acid contents of glycoproteins
by high-pH anion-exchange chromatography with pulsed amperometric
detection. Glycobiology 8: 35–43.
24. Packer NH, Lawson MA, Jardine DR, Redmond JW (1998) A general approach
to desalting oligosaccharides released from glycoproteins. Glycoconj J 15:
737–747.
25. Papac DI, Wong A, Jones AJ (1996) Analysis of acidic oligosaccharides and
glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Anal Chem 68: 3215–3223.
26. Zhang X, Shi L, Shu S, Wang Y, Zhao K, et al. (2007) An improved method of
sample preparation on AnchorChip targets for MALDI-MS and MS/MS and its
application in the liver proteome project. Proteomics 7: 2340–2349.
27. Stubiger G, Marchetti M, Nagano M, Grimm R, Gmeiner G, et al. (2005)
Characterization of N- and O-glycopeptides of recombinant human erythro-
poietins as potential biomarkers for doping analysis by means of microscale
sample purification combined with MALDI-TOF and quadrupole IT/RTOF
mass spectrometry. J Sep Sci 28: 1764–1778.
28. Hagglund P, Bunkenborg J, Elortza F, Jensen ON, Roepstorff P (2004) A new
strategy for identification of N-glycosylated proteins and unambiguous
assignment of their glycosylation sites using HILIC enrichment and partial
deglycosylation. J Proteome Res 3: 556–566.
29. Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, et al. (2007) Comparison of
the methods for profiling glycoprotein glycans–HUPO Human Disease
Glycomics/Proteome Initiative multi-institutional study. Glycobiology 17:
411–422.
30. Wuhrer M, Catalina MI, Deelder AM, Hokke CH (2007) Glycoproteomics
based on tandem mass spectrometry of glycopeptides. J Chromatogr B Analyt
Technol Biomed Life Sci 849: 115–128.
31. Llop E, Gallego RG, Belalcazar V, Gerwig GJ, Kamerling JP, et al. (2007)
Evaluation of protein N-glycosylation in 2-DE: Erythropoietin as a study case.
Proteomics 7: 4278–4291.
32. Mills PB, Mills K, Johnson AW, Clayton PT, Winchester BG (2001) Analysis by
matrix assisted laser desorption/ionisation-time of flight mass spectrometry of
the post-translational modifications of alpha 1-antitrypsin isoforms separated by
two-dimensional polyacrylamide gel electrophoresis. Proteomics 1: 778–786.
33. Sparbier K, Koch S, Kessler I, Wenzel T, Kostrzewa M (2005) Selective
isolation of glycoproteins and glycopeptides for MALDI-TOF MS detection
supported by magnetic particles. J Biomol Tech 16: 407–413.
34. Harvey DJ (1993) Quantitative aspects of the matrix-assisted laser desorption
mass spectrometry of complex oligosaccharides. Rapid Commun Mass
Spectrom 7: 614–619.
35. Sung HJ, Cho JY (2008) Biomarkers for the lung cancer diagnosis and their
advances in proteomics. BMB Rep 41: 615–625.
Improved Analysis of Gel-Separated Glycoproteins
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e15096